Search - tctmd.com

Displaying 21 - 40 of 83

Sort: Relevancy | Date

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

October 13, 2021

COVID-19: TCTMD’s Dispatch for October Week 2

News Daily News

COVID-19: TCTMD’s Dispatch for October Week 2

October 11, 2021

Episode 129: The TICO-STEMI Trial

Podcast TCTMD Talking Points

The TICO-STEMI Trial

October 06, 2021

AHA: More Screening Needed to Catch Myocardial Injury After Noncardiac Surgery

News Daily News

AHA: More Screening Needed to Catch Myocardial Injury After Noncardiac Surgery

Yael L. Maxwell

October 04, 2021

October 2021 News Roundup

News Opinion CV Team Dispatch

October 2021 News Roundup

October 01, 2021

Women Stand to Gain the Most From Standardized STEMI Protocols

News Daily News

Women Stand to Gain the Most From Standardized STEMI Protocols

Michael O'Riordan

September 30, 2021

High Burden of CAD in Chest Pain Patients With ‘Normal’ Troponin

News Daily News

High Burden of CAD in Chest Pain Patients With ‘Normal’ Troponin

Michael O'Riordan

September 27, 2021

Could an App Replace Statin Prescribing by Doctors?

News Daily News

Could an App Replace Statin Prescribing by Doctors?

Michael O'Riordan

September 08, 2021

New ESC Prevention Guidelines Focus on Tailored, Escalating Therapy

News Conference News ESC 2021

New ESC Prevention Guidelines Focus on Tailored, Escalating Therapy

Michael O'Riordan

September 03, 2021

Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention

News Conference News ESC 2021

Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention

Michael O'Riordan

August 31, 2021

‘Quadpill’ Beats Monotherapy at BP Lowering: QUARTET

News Conference News ESC 2021

‘Quadpill’ Beats Monotherapy at BP Lowering: QUARTET

August 31, 2021

Amulet IDE: LAA Occluder Performs Well Against Watchman

News Conference News ESC 2021

Amulet IDE: LAA Occluder Performs Well Against Watchman

August 30, 2021

ENVISAGE-TAVI AF: Edoxaban Disappoints in TAVI Setting

News Conference News ESC 2021

ENVISAGE-TAVI AF: Edoxaban Disappoints in TAVI Setting

August 28, 2021

MASTER DAPT: One Month's Enough in Patients at High Bleeding Risk

News Conference News ESC 2021

MASTER DAPT: One Month's Enough in Patients at High Bleeding Risk

August 28, 2021

Colchicine Lowers CVD Risk No Matter When Past ACS Occurred: LoDoCo2

News Daily News

Colchicine Lowers CVD Risk No Matter When Past ACS Occurred: LoDoCo2

Michael O'Riordan

August 26, 2021

The TIPS-3 Trial

Podcast TCTMD Talking Points

The TIPS-3 Trial

August 18, 2021

Largest Study of VITT After COVID-19 Vaccination Digs Into Lab, Clinical Features

News Daily News

Largest Study of VITT After COVID-19 Vaccination Digs Into Lab, Clinical Features

August 11, 2021

Rivaroxaban Safe, Effective in Renal Disease: VOYAGER PAD

News Daily News

Rivaroxaban Safe, Effective in Renal Disease: VOYAGER PAD

August 10, 2021

PAD Continues to Elude Clinicians, Despite Gains: AHA

News Daily News

PAD Continues to Elude Clinicians, Despite Gains: AHA

August 05, 2021

STROKE-VT: DOACs Cut Cerebrovascular Events After LV Arrhythmia Ablation

News Conference News HRS 2021

STROKE-VT: DOACs Cut Cerebrovascular Events After LV Arrhythmia Ablation

July 29, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.